# Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis

> **NCT07335887** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 39 (estimated)

## Conditions studied

- AL Amyloidosis (AL)
- t(11;14) Positive

## Interventions

- **DRUG:** sonrotoclax
- **DRUG:** Daratumumab
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT07335887
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2028-02-29
- **Final completion:** 2029-01-31
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07335887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07335887, "Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07335887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*